Gemcitabine Hydrochloride Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Gemcitabine Hydrochloride Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Gemcitabine Hydrochloride Market is expected to register a CAGR of 7.1% during the forecast period.

COVID-19 pandemic had a substantial impact on patients with underlying diseases, gemcitabine was shown to have both anti-cancer and anti-viral activity. The strict lockdowns and government regulations intended to slow down the spread of COVID-19 resulted in the boost of the gemcitabine hydrochloride market along with balancing the strain on the healthcare system globally. In wake of the COVID-19 outbreak, gemcitabine hydrochloride acted as an anti-cancerous along with decreasing the potential of infectious exposures.

The article published in Pubmed titled ‘Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2’ in February 2021 stated that the difluoro group of gemcitabine is critical for the antiviral activity and its combination with other evaluated antiviral drugs, such as remdesivir, could be a desirable option to treat SARS-CoV-2 infection.

As per the article published in JAMA Network titled ‘Association of Antineoplastic Therapy With Decreased SARS-CoV-2 Infection Rates in Patients With Cancer’ in August 2021 stated antineoplastic compounds that target cellular machinery used by SARS-CoV-2 for entry and replication may disrupt SARS-CoV-2 activity, gemcitabine treatment was associated with reduced SARS-CoV-2 infection. Patients given gemcitabine demonstrated statistically significant lower SARS-CoV-2 positivity rates compared with patients given other antineoplastics. Thus, the COVID-19 outbreak had a positive impact on the gemcitabine hydrochloride market.

The gemcitabine hydrochloride market is expected to grow in coming years due to the significant increase in cancer prevalance globally. Further, increased awareness about cancer and patient support programs are among the major factors driving the growth of the studied market. For instance, the International Agency for Research on Cancer (IARC) is marking Childhood Cancer Awareness month during September by highlighting the global burden of childhood cancer and IARC’s actions to prevent and address childhood cancer worldwide.

According to estimates from the IARC Global Cancer Observatory, in 2020 almost 280,000 children and adolescents (aged 0–19 years) were diagnosed with cancer worldwide and almost 110,000 children died from cancer. However, the actual numbers may be much higher, because in many countries childhood cancer is difficult to diagnose. Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, the stringent regulatory framework is likely to impede the market growth.

Key Market TrendsLung Cancer is Expected to Witness Significant Growth Over the Forecast Period

Lung cancer is the second most common cancer worldwide. It is the most common cancer in men and the second most common cancer in women. According to Globcan 2020, the incidence rate of lung cancer is about 11.4% for all ages and both sex. About 18% of deaths accounted for lung cancer in 2020 which is the highest among all prevailing cancer.

According to an article published in National Library of Medicine titled 'Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study' in August 2021 reported that combination therapy of gemcitabine with a platinum agent is a highly effective treatment among the platinum doublet regimens and is promising as a treatment for advanced squamous cell lung carcinoma. Thus, such research activities will lead to verticle growth in the coming future.

Innovent Biologics and Eli Lilly and Company jointly announced that the National Medical Products Administration (NMPA) of China has approved the supplemental New Drug Application (sNDA) for Tyvyt (sintilimab injection) in combination with gemcitabine and platinum chemotherapy as first-line therapy for people with unresectable locally advanced or metastatic squamous non-small cell lung cancer (sqNSCLC). The new product approval for lung cancer along with gemcitabine will boost the segment in the forcasted year.

Thus, high prevalance of lung cancer, research and development associated with lung cancer, and lower side effects of gemcitabine are expected to boost the Lung cancer segment in the forecasted year.

North America is Expected to Dominate the Gemcitabine hydrochloride Market

North America is expected to hold a major market share in the global gemcitabine hydrochloride market due to the increasing burden of cancer diseases and advancements in products. The low cost of generic gemcitabine hydrochloride and reformulation strategies adopted by companies are among the other driving factor for market growth

An article published in Frontiers titled ‘Efficacy, Safety, and Cost-Minimization Analysis of Continuous Infusion of Low-Dose Gemcitabine Plus Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma’ in April 2021 stated that low-dose Gemcitabine plus Cisplatin is an effective and safe treatment option for patients with unresectable malignant pleural mesothelioma; besides, this combination is a cost-saving option when compared with other frequently used chemotherapy schemes. Therefore, this treatment scheme should be strongly considered for patients with unresectable malignant pleural mesothelioma and limited economic resources.

In June 2022, Fujifilm announced that it has begun implementation of a phase 2 study in the United States to evaluate safety, tolerability, and preliminary efficacy of FF-10832, a liposomal drug candidate, in combination therapy with Merck & Co Keytruda (pembrolizumab) for patients with advanced solid tumors. FF-10832 is a liposomal formulation which encapsulates gemcitabine, an approved anti-cancer agent indicated for the treatment of a variety of solid tumors.

Additionally, in April 2022, Tiziana Life Sciences announced that filing of Investigation new drug application and initiation of Phase 2 trial in KRAS (Kirsten rat sarcoma viral) + NSCLC (Non-small cell lung cancer) patients with combination of milciclib + gemcitabine. The positive outcome of such clinical trials may lead to new treatment option, thereby increasing the regional growth.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.

Competitive Landscape

The Gemcitabine Hydrochloride Market is fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Eli Lilly & Co., Accord Healthcare Inc., Pfizer Inc. (Hospira Inc.), Apotex Inc., Fresenius Kabi USA, Gland Pharma Ltd., Mylan Pharmaceuticals Inc., Sagent Pharmaceuticals Inc., Teva Pharmaceuticals Ltd., and Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.